Condition: OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma · Sponsor: Lixia Sheng
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.
This description comes directly from the study's public registry record.
Lixia Sheng, Doctor · 86-574-87085596 · slx800408@163.com
Chen · 86-574-87085111 · nbyykyk@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital | Hangzhou, Zhejiang, China | Recruiting |
| 86-574-87085596 | Ningbo, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Ningbo University | Ningbo, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06134284